Circulating Biomarkers and Recurrence of Persistent Atrial Fibrillation After Electrical Cardioversion.

ABSTRACT:

Background

Rhythm control therapy is recommended for individuals with symptomatic atrial fibrillation (AF) to reduce symptoms and improve quality of life. Electrical cardioversion (ECV) is used to restore sinus rhythm (SR), but AF recurrence is common.

Objective

We aimed to investigate if a selection of circulating biomarkers can predict rhythm outcomes in individuals with persistent AF treated with ECV.

Design

This was an observational cohort study.

Methods

We included 200 individuals aged ⩾ 18 years referred for ECV of AF from November 2017 to March 2022. We obtained blood samples 0 to 6 weeks before ECV. Plasminogen activator inhibitor type 1 (PAI-1) activity, soluble suppression of tumorigenicity 2 (sST2), galectin-3 (GAL-3), interleukin-6 (IL-6), matrix me

SUBMITTER: Andersen EL 

PROVIDER: S-EPMC12432329 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature